1

W R Grace Co Jobs in Austin, TX (NOW HIRING)

W R Grace Co information

See Austin, TX salary details

$9

$25

$44

How much do w r grace co jobs pay per hour?

As of Aug 10, 2026, the average hourly pay for w r grace co in Austin, TX is $25.03, according to ZipRecruiter salary data. Most workers in this role earn between $19.04 and $27.64 per hour, depending on experience, location, and employer.

What career advancement opportunities are available at W R Grace Co for early-career professionals?

At W. R. Grace & Co., early-career professionals can benefit from a variety of career advancement opportunities, such as formal mentoring programs, rotational assignments, and internal job postings that encourage skill development across different business units. The company places a strong emphasis on professional growth, often supporting continuing education and professional certifications. Employees are encouraged to collaborate across departments, which helps to broaden their experience and visibility within the organization. Advancement is typically merit-based, with high performers frequently being considered for leadership development programs and promotions.

What is W R Grace Co?

W. R. Grace & Co. is a global specialty chemicals and materials company. The company primarily produces catalysts, engineered materials, and specialty chemicals used in a wide range of industries, including refining, petrochemicals, pharmaceuticals, and food packaging. Grace is well-known for its innovations in chemical processing technologies and its products that help improve production efficiency and environmental performance. Founded in 1854, the company has a long history of serving customers worldwide with high-performance chemical solutions.

What skills and qualifications are needed to thrive as a chemical engineer at W R Grace Co?

To thrive as a Chemical Engineer at W. R. Grace & Co., you need a solid background in chemical engineering principles, process design, and a relevant engineering degree. Familiarity with process simulation software, statistical analysis tools, and safety management systems is often required. Strong problem-solving abilities, teamwork, and effective communication distinguish top performers in this role. These skills are essential for optimizing manufacturing processes, ensuring product quality, and maintaining safe and efficient operations.

What is the difference between W R Grace Co vs Chemical Plant Operator?

AspectW R Grace CoChemical Plant Operator
Required CredentialsHigh school diploma, technical training, safety certificationsHigh school diploma, technical training, safety certifications
Work EnvironmentManufacturing plants, chemical production facilitiesChemical manufacturing plants, processing facilities
Industry UsageChemical manufacturing, specialty chemicalsChemical production, industrial processing
Common Search/ComparisonW R Grace Co vs Chemical Plant Operator

Both roles typically require similar credentials such as a high school diploma and safety certifications. They work in chemical manufacturing environments and are involved in operating and maintaining chemical processing equipment. The main difference lies in W R Grace Co being a specific employer, while Chemical Plant Operator is a broader job title used across many companies in the industry.

What are popular job titles related to W R Grace Co jobs in Austin, TX? For W R Grace Co jobs in Austin, TX, the most frequently searched job titles are:
What job categories do people searching W R Grace Co jobs in Austin, TX look for? The top searched job categories for W R Grace Co jobs in Austin, TX are:
What cities near Austin, TX are hiring for W R Grace Co jobs? Cities near Austin, TX with the most W R Grace Co job openings:
Infographic showing various W R Grace Co job openings in Austin, TX as of August 2026, with employment types broken down into 100% Full Time. Highlights an 100% In-person job distribution, with an average salary of $52,055 per year, or $25 per hour.

Next Generation Virucides - Peptoids

Maxwell Biosciences

Austin, TX • On-site

Other

Re-posted 16 days ago


Job description

Next Generation Virucides – Peptoids

Maxwell Biosciences is developing a new class of potent, safe, biostable synthetic peptide-like small molecules currently in toxicology testing to treat common viral infections in humans. Read more about how peptoids mimic natural virucides.

Maxwell's new drug class includes multiple drug candidates based on naturally occurring immune peptides, but with side chains appended to backbone nitrogens instead of carbon. The nitrogen bond is stronger than a carbon bond, and these novel peptoid ("peptide-like") synthetic virucides have been shown to irreversibly inactivate viral DNA at low doses. Early preclinical data also shows safety as a potential therapeutic for humans.

Novel, Patented Technology Maxwell's lead virucidal peptoids are designed to serve as structural, functional, and mechanistic mimics of natural virucidal peptides used by the human immune system to defend against pathogens. This virucidal peptoid class is protected by a granted patent assigned to Maxwell Biosciences by the US Department of Energy and US National Institutes of Health.

We have published the design, characterization, anti-infective activity, and biomimetic mechanisms of synthetic anti-infective peptoids in major peer-reviewed journals. Synthetic virucidal peptoids are synthesized at low cost on a robotic synthesizer and can be scaled up easily, with facile access to high chemical diversity. In their ease of synthesis, peptoids are unique among peptide mimetics. To identify our lead candidates (6mer-13mers), 70 different short synthetic anti-infective peptoids were synthesized, purified, and tested against viruses, 47 different bacterial microorganisms, including wild-type and drug-resistant variants. Many of our anti-infective peptoid drug candidates are as potent as well-known anti-infective drugs currently approved by the FDA (0.4-6.5 µM minimum inhibitory concentrations, MICs). The minimum inhibitory concentration is the smallest amount of a drug necessary to prevent visible growth of the pathogen.

The biomimetic mechanism of action of anti-infective peptoids was shown using a wide range of biophysical tools, including studies of pathogen membranes and DNA, using scanning electron microscopy, transmission electron microscopy, and soft X-ray tomography of untreated vs. treated pathogens. We used super-resolution fluorescence microscopy to show that our lead drug candidates penetrate negatively charged membranes and cause rapid-onset solidification of negatively charged DNA and RNA; this mechanism is identical to that of the human peptide, the cathelicidin LL-37. Due to the mechanism of action, the likelihood of pathogenic resistance emerging to synthetic peptoid candidates may be less than that of conventional drugs, which have more specific molecular targets.

Dr Annelise Barron is the primary inventor and scientific co-founder of Maxwell Biosciences. Below is a list of the publications that have published her work as well as the work of other scientists who are building upon her research using Maxwell's patented peptoid drug class. This data shows the advantages of using peptoids as broad spectrum anti-infectives and how peptoid anti-infectives mimic antimicrobial peptides.

  • Helical side chain chemistry of a peptoid-based SP-C analogue: Balancing structural rigidity and biomimicry. BIOPOLYMERS Brown, N. J., Lin, J. S., Barron, A. E. 2019: e23277
  • Effective in vivo treatment of acute lung injury with helical, amphipathic peptoid mimics of pulmonary surfactant proteins SCIENTIFIC REPORTS Czyzewski, A. M., McCaig, L. M., Dohm, M. T., Broering, L. A., Yao, L., Brown, N. J., Didwania, M. K., Lin, J. S., Lewis, J. F., Veldhuizen, R., Barron, A. E. 2018; 8: 6795
  • Intracellular biomass flocculation as a key mechanism of rapid bacterial killing by cationic, amphipathic antimicrobial peptides and peptoids. SCIENTIFIC REPORTS Chongsiriwatana, N. P., Lin, J. S., Kapoor, R., Wetzler, M., Rea, J. A., Didwania, M. K., Contag, C. H., Barron, A. E. 2017; 7 (1): 16718
  • In Vivo, In Vitro, and In Silico Characterization of Peptoids as Antimicrobial Agents PLOS ONE Czyzewski, A. M., Jenssen, H., Fjell, C. D., Waldbrook, M., Chongsiriwatana, N. P., Yuen, E., Hancock, R. E., Barron, A. E.2016; 11 (2): 1-17
  • In Vivo Biodistribution and Small Animal PET of Cu-64-Labeled Antimicrobial Peptoids BIOCONJUGATE CHEMISTRY Seo, J., Ren, G., Liu, H., Miao, Z., Park, M., Wang, Y., Miller, T. M., Barron, A. E., Cheng, Z. 2012; 23 (5): 1069-1079
  • Peptoid transporters: effects of cationic, amphipathic structure on their cellular uptake MOLECULAR BIOSYSTEMS Huang, W., Seo, J., Lin, J. S., Barron, A. E. 2012; 8 (10): 2626-2628
  • Efficacy of Antimicrobial Peptoids against Mycobacterium tuberculosis ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Kapoor, R., Eimerman, P. R., Hardy, J. W., Cirillo, J. D., Contag, C. H., Barron, A. E. 2011; 55 (6): 3058-3062
  • Antimicrobial Peptoids Are Effective against Pseudomonas aeruginosa Biofilms ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Kapoor, R., Wadman, M. W., Dohm, M. T., Czyzewski, A. M., Spormann, A. M., Barron, A. E. 2011; 55 (6): 3054-3057
  • Short Alkylated Peptoid Mimics of Antimicrobial Lipopeptides ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Chongsiriwatana, N. P., Miller, T. M., Wetzler, M., Vakulenko, S., Karlsson, A. J., Palecek, S. P., Mobashery, S., Barron, A. E. 2011; 55 (1): 417-420

Joshua McClure